T-Ray Science, Inc. is a medical device company committed to developing innovative systems for the early detection of cancer.The Company's initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma. The Company has licensed a technology developed by the BC Cancer Agency for in vivo, real-time, non-invasive skin measurements. Our platform technology is also fully extensible to early detection systems for other types of cancer.
T-Ray Science, Inc. was incorporated in March 2006 to bring together a team of high-level academic researchers, medical device industry experts, and corporate finance professionals to execute a targeted product strategy focused on the early detection of cancer. The Company's initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma. The Company has exclusive world wide rights to a technology developed by the BC Cancer Agency and the University of British Columbia Faculty of Medicine for in vivo, real-time, non-invasive skin lesion measurements. The Company has set the milestone of completion of a commercial prototype of our skin cancer detection device, Verisānte™ | Aura™ by April 2011 with commercial manufacturing by September 2011
Our platform technology is also fully extensible to early detection systems for other types of cancer, including lung, gastro-intestinal, colorectal and cervical cancers. The Company anticipates development and manufacture of a low cost commercial prototype of a lung cancer detection device, Verisānte™ | Core™ will commence mid 2011.
In 2008, the Company filed five patents, including a patent on the world's first continuous-wave (CW) terahertz spectrometer. The Company also signed an exclusive license agreement with MIT on what is believed to be the best method of creating CW THz waves. T-Ray is using this technology for its own in house research and development and is and is offering sublicense agreements to Companies developing applications using continuous wave technology.
The company, identifies 3 current product platforms:
________
Verisānte™ | Aura™
The Verisānte™ | Aura™ series is a novel multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. The system provides valuable information about the chemical composition of the skin quickly and non-invasively. Verisānte™ | Aura™ scans for 21 different cancer biomarkers in less than one second; providing immediate, accurate results.
Jointly developed by the BC Cancer Agency and the University of British Columbia Faculty of Medicine, this patent protected technology has already been used in a human clinical study spanning six years on approximately 1,000 lesions. Intermediate results have shown the technology to have identified 100% melanomas (sensitivity of 100% and specificity of 70%). This diagnostic tool will greatly aid healthcare professionals, lowering healthcare costs through reduced wait times and early detection.
Verisānte™ | Aura™ will help to automate the current process of diagnosis, allowing rapid scanning of the 20-40 skin lesions on at-risk individuals. Patients will no longer need to suffer through long wait times to see a dermatologist, as scans may be accomplished quickly by trained technicians or assistants. Verisānte™ | Aura™ will decrease patient wait times, thereby increasing the standard of care; while also decreasing healthcare costs by detecting skin cancer in its early, most easily treatable stages.
T-Ray has brought together a product development team lead by award-winning pioneers in the field of cancer imaging and we also have world renowned experts in early cancer detection involved with our technical and medical team.
T-Ray will complete a production prototype of Verisānte™ | Aura™ by April 2011, with commercial units ready for clinical trials and sale where authorized by September 2011.
Verisānte™ | Core
The Verisānte™ | Core™ series utilizes the platform technology behind the Verisānte™ | Aura™ for the early detection of other cancers including lung, colon and cervical, using an endoscopic attachment.
T-Ray Science, Inc. is a medical device company committed to developing innovative systems for the early detection of cancer.The Company's initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma. The Company has licensed a technology developed by the BC Cancer Agency for in vivo, real-time, non-invasive skin measurements. Our platform technology is also fully extensible to early detection systems for other types of cancer.
T-Ray Science, Inc. was incorporated in March 2006 to bring together a team of high-level academic researchers, medical device industry experts, and corporate finance professionals to execute a targeted product strategy focused on the early detection of cancer. The Company's initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma. The Company has exclusive world wide rights to a technology developed by the BC Cancer Agency and the University of British Columbia Faculty of Medicine for in vivo, real-time, non-invasive skin lesion measurements. The Company has set the milestone of completion of a commercial prototype of our skin cancer detection device, Verisānte™ | Aura™ by April 2011 with commercial manufacturing by September 2011
Our platform technology is also fully extensible to early detection systems for other types of cancer, including lung, gastro-intestinal, colorectal and cervical cancers. The Company anticipates development and manufacture of a low cost commercial prototype of a lung cancer detection device, Verisānte™ | Core™ will commence mid 2011.In 2008, the Company filed five patents, including a patent on the world's first continuous-wave (CW) terahertz spectrometer. The Company also signed an exclusive license agreement with MIT on what is believed to be the best method of creating CW THz waves. T-Ray is using this technology for its own in house research and development and is and is offering sublicense agreements to Companies developing applications using continuous wave technology.
The company, identifies 3 current product platforms:
________
Verisānte™ | Aura™
The Verisānte™ | Aura™ series is a novel multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. The system provides valuable information about the chemical composition of the skin quickly and non-invasively. Verisānte™ | Aura™ scans for 21 different cancer biomarkers in less than one second; providing immediate, accurate results.Jointly developed by the BC Cancer Agency and the University of British Columbia Faculty of Medicine, this patent protected technology has already been used in a human clinical study spanning six years on approximately 1,000 lesions. Intermediate results have shown the technology to have identified 100% melanomas (sensitivity of 100% and specificity of 70%). This diagnostic tool will greatly aid healthcare professionals, lowering healthcare costs through reduced wait times and early detection.
Verisānte™ | Aura™ will help to automate the current process of diagnosis, allowing rapid scanning of the 20-40 skin lesions on at-risk individuals. Patients will no longer need to suffer through long wait times to see a dermatologist, as scans may be accomplished quickly by trained technicians or assistants. Verisānte™ | Aura™ will decrease patient wait times, thereby increasing the standard of care; while also decreasing healthcare costs by detecting skin cancer in its early, most easily treatable stages.
T-Ray has brought together a product development team lead by award-winning pioneers in the field of cancer imaging and we also have world renowned experts in early cancer detection involved with our technical and medical team.
T-Ray will complete a production prototype of Verisānte™ | Aura™ by April 2011, with commercial units ready for clinical trials and sale where authorized by September 2011.
Verisānte™ | Core
The Verisānte™ | Core™ series utilizes the platform technology behind the Verisānte™ | Aura™ for the early detection of other cancers including lung, colon and cervical, using an endoscopic attachment.
The optical biopsy system, known as the Verisānte™ | Core™ series, detects spectral bio-markers for cancer. Today, once a doctor spots a lung lesion, it must be surgically biopsied for a full pathology report to determine if it is malignant. However, the Verisānte™ | Core™ device determines with exceptional accuracy if a lesion is malignant or benign. Through this quick and non-invasive verification process, the Verisānte™ Core™ device prevents unnecessary biopsies and the resulting stress and health-care risks and costs that accompany the biopsy procedure.
In addition to our existing collaborations with the BC Cancer Agency, T-Ray will collaborate with Dr. Stephen Lam and the VGH Lung Centre for the development and commercialization of Verisānte™ | Core™ for the early detection of lung cancer. We expect manufacturing of a low cost commercial prototype to begin in mid 2011.
Authenticare™
Authenticare™ is T-Ray's pre-production prototype of a pharmaceutical tablet analyzer for the authentication of solid dosage pharmaceuticals.
The target markets for the device are pharmacies, consumers, law enforcement, corporate security, and others who need to identify counterfeit drugs that otherwise appear identical to the brand name drugs. According to the Center for Medicines in the Public Interest, global counterfeit drug sales will reach US $75 billion by 2010.
With Authenticare™, T-Ray Science is seeking to bring an affordable, portable, non-destructive solution to market which allows users to easily verify tablet authenticity. Authenticare™ connects to a standard laptop computer for control and readout.
The technology Authenticare™ is based on is a result of a successful collaboration with scientists at the University of Waterloo. In 2008, T-Ray Science filed two patent applications for hardware and software used by Authenticare™. Beginning in 2009, the design and production services of Sanmina-SCI Corporation of California were also utilized in the development of Authenticare™. The device will now undergo rigorous validation, safety, and field testing.
The target markets for the device are pharmacies, consumers, law enforcement, corporate security, and others who need to identify counterfeit drugs that otherwise appear identical to the brand name drugs. According to the Center for Medicines in the Public Interest, global counterfeit drug sales will reach US $75 billion by 2010.
With Authenticare™, T-Ray Science is seeking to bring an affordable, portable, non-destructive solution to market which allows users to easily verify tablet authenticity. Authenticare™ connects to a standard laptop computer for control and readout.
The technology Authenticare™ is based on is a result of a successful collaboration with scientists at the University of Waterloo. In 2008, T-Ray Science filed two patent applications for hardware and software used by Authenticare™. Beginning in 2009, the design and production services of Sanmina-SCI Corporation of California were also utilized in the development of Authenticare™. The device will now undergo rigorous validation, safety, and field testing.
No comments:
Post a Comment